Abstract
The pharmacokinetic characteristics of cannabidiol are described and the interaction effects of concomitant antiseizure medications on cannabidiol in terms of its pharmacokinetics and pharmacodynamics are highlighted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Patsalos PN, Szaflarski JP, Gidal B, VanLandingham K, Critchley D, Morrison G. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. Epilepsia. 2020;61:1854–68.
Summary of product characteristics: Cannabidiol (Epidyolex). GW Pharma Ltd. Last update 27 July 2020.
Morrison G, Crockett J, Blakey G, Sommerville K. A phase I, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Develop. 2019;8:1009–31.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patsalos, P.N. (2022). Cannabidiol. In: Antiseizure Medication Interactions. Springer, Cham. https://doi.org/10.1007/978-3-030-82790-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-82790-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82789-2
Online ISBN: 978-3-030-82790-8
eBook Packages: MedicineMedicine (R0)